ArticleJournal of medical biochemistry2026
Clinical implications of vasoactive intestinal peptide and 5-hydroxytryptamine in diabetic neurogenic bladder and their relationship with post-void residual.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To elucidate the clinical significance of vasoactive intestinal peptide (VIP) and 5-hydroxytryptamine (5-HT) in diabetic neurogenic bladder (DNB). We aimed to determine the diagnostic, stratifying, and prognostic value of their simultaneous detection, and to reveal the dynamic associations of these biomarkers with post-void residual urine volume (PVR). Methods: The study population consisted of 30 DNB patients and 30 healthy individuals from the same timeframe (June 2024-April 2025). Laboratory assessments quantified serum VIP concentration by enzyme-linked immunosorbent assay (ELISA) and 5-HT concentration by liquid chromatography-mass spectrometry (LC-MS). PVR quantification relied on urodynamic examination and abdominal ultrasound. Over a 3-month follow-up, serial measurements of VIP and 5-HT were obtained. Statistical analyses, including Pearson correlation, receiver operating characteristic (ROC) curve analysis, and logistic regression modeling, were employed to assess the relationships of these biomarkers with PVR, bladder function classification, and patient prognosis. Results: Significant reductions in VIP and 5-HT were observed in DNB patients relative to controls (P< 0.05). The combined use of VIP and 5-HT achieved an area under the curve (AUC) value of 0.878, with 83.33% sensitivity and 86.67% specificity, indicating better diagnostic efficacy than single-marker detection (P< 0.05). VIP and 5-HT levels were inversely related to PVR (P< 0.05). In DNB patients, both biomarkers increased gradually at one and three months post-treatment (P< 0.05), paralleling urodynamic improvements. Stratification by bladder dysfunction severity (mild, moderate, severe) revealed a progressive decline in VIP and 5-HT levels with increasing severity (P < 0 .0 5), confirming their utility in disease staging. Patients with lower VIP and 5-HT levels three months after treatment had a greater propensity for upper urinary tract impairment, urinary tract infections, and disease advancement. Conclusions: The combined detection of VIP and 5-HT enables effective evaluation of DNB severity, forecasts disease progression, and offers a foundation for timely intervention through dynamic monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.